Second malignancies diagnosed in patients receiving chemotherapy at the pennsylvania hospital

H. Lerner, E. Marcovitz, D. Schoenfeld, Howard A. Zaren

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

During the past 15 years, the records of 2,020 patients who received chemotherapy on the surgical oncology, chemotherapy service at the Pennsylvania Hospital were reviewed. Thirty‐five patients had pathologically confirmed second independent malignant tumors (not recurrences). The second cancers that developed were varied. The patients who developed these second malignancies ranged in age from 35 to 77 years (24 females, 11 males). The time interval involved was two to 102 months. Nine patients in this group of second malignancies received prior radiation therapy. The following is a list of the second cancers. There were 8 colons, 5 ovaries, 5 lungs, 6 acute myelogenous leukemias, 1 esophagus, 2 bladders, 2 epidermoid carcinomas of the skin, 2 melanomas, 1 chronic lymphatic leukemia, 1 breast cancer, 1 non‐Hodgkin's malignant lymphoma, and 1 stomach cancer. The majority of second malignant tumors were amenable to some form of therapy, ie, surgery, radiation or chemotherapy. However, all of the acute myelogenous leukemias were totally refractory to any therapeutic modalities and rapidly expired. The majority of second cancers developed in patients receiving adjuvant chemotherapy. This is a patient population with a much longer expected survival time, particularly when compared to patients receiving chemotherapy for advanced disease. Twenty‐five of the 34 second cancers developed in patients who received adjuvant chemotherapy for breast (14) or colorectal (11) cancers. The etiology of the second malignancies is very difficult to determine. However, alkylating agents appeared to be the possible etiologic agent involved in the development of acute myelogenous leukemia.

Original languageEnglish (US)
Pages (from-to)195-197
Number of pages3
JournalJournal of Surgical Oncology
Volume23
Issue number3
DOIs
StatePublished - Jan 1 1983

Fingerprint

Second Primary Neoplasms
Drug Therapy
Acute Myeloid Leukemia
Adjuvant Chemotherapy
Alkylating Agents
B-Cell Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
Esophagus
Stomach Neoplasms
Squamous Cell Carcinoma
Colorectal Neoplasms
Ovary
Melanoma
Lymphoma
Neoplasms
Colon
Urinary Bladder
Breast
Radiotherapy
Radiation

Keywords

  • 35 second malignancies
  • chemotherapy
  • patients

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Second malignancies diagnosed in patients receiving chemotherapy at the pennsylvania hospital. / Lerner, H.; Marcovitz, E.; Schoenfeld, D.; Zaren, Howard A.

In: Journal of Surgical Oncology, Vol. 23, No. 3, 01.01.1983, p. 195-197.

Research output: Contribution to journalArticle

Lerner, H. ; Marcovitz, E. ; Schoenfeld, D. ; Zaren, Howard A. / Second malignancies diagnosed in patients receiving chemotherapy at the pennsylvania hospital. In: Journal of Surgical Oncology. 1983 ; Vol. 23, No. 3. pp. 195-197.
@article{41c24b21597548b0873f461928d9b92c,
title = "Second malignancies diagnosed in patients receiving chemotherapy at the pennsylvania hospital",
abstract = "During the past 15 years, the records of 2,020 patients who received chemotherapy on the surgical oncology, chemotherapy service at the Pennsylvania Hospital were reviewed. Thirty‐five patients had pathologically confirmed second independent malignant tumors (not recurrences). The second cancers that developed were varied. The patients who developed these second malignancies ranged in age from 35 to 77 years (24 females, 11 males). The time interval involved was two to 102 months. Nine patients in this group of second malignancies received prior radiation therapy. The following is a list of the second cancers. There were 8 colons, 5 ovaries, 5 lungs, 6 acute myelogenous leukemias, 1 esophagus, 2 bladders, 2 epidermoid carcinomas of the skin, 2 melanomas, 1 chronic lymphatic leukemia, 1 breast cancer, 1 non‐Hodgkin's malignant lymphoma, and 1 stomach cancer. The majority of second malignant tumors were amenable to some form of therapy, ie, surgery, radiation or chemotherapy. However, all of the acute myelogenous leukemias were totally refractory to any therapeutic modalities and rapidly expired. The majority of second cancers developed in patients receiving adjuvant chemotherapy. This is a patient population with a much longer expected survival time, particularly when compared to patients receiving chemotherapy for advanced disease. Twenty‐five of the 34 second cancers developed in patients who received adjuvant chemotherapy for breast (14) or colorectal (11) cancers. The etiology of the second malignancies is very difficult to determine. However, alkylating agents appeared to be the possible etiologic agent involved in the development of acute myelogenous leukemia.",
keywords = "35 second malignancies, chemotherapy, patients",
author = "H. Lerner and E. Marcovitz and D. Schoenfeld and Zaren, {Howard A.}",
year = "1983",
month = "1",
day = "1",
doi = "10.1002/jso.2930230315",
language = "English (US)",
volume = "23",
pages = "195--197",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Second malignancies diagnosed in patients receiving chemotherapy at the pennsylvania hospital

AU - Lerner, H.

AU - Marcovitz, E.

AU - Schoenfeld, D.

AU - Zaren, Howard A.

PY - 1983/1/1

Y1 - 1983/1/1

N2 - During the past 15 years, the records of 2,020 patients who received chemotherapy on the surgical oncology, chemotherapy service at the Pennsylvania Hospital were reviewed. Thirty‐five patients had pathologically confirmed second independent malignant tumors (not recurrences). The second cancers that developed were varied. The patients who developed these second malignancies ranged in age from 35 to 77 years (24 females, 11 males). The time interval involved was two to 102 months. Nine patients in this group of second malignancies received prior radiation therapy. The following is a list of the second cancers. There were 8 colons, 5 ovaries, 5 lungs, 6 acute myelogenous leukemias, 1 esophagus, 2 bladders, 2 epidermoid carcinomas of the skin, 2 melanomas, 1 chronic lymphatic leukemia, 1 breast cancer, 1 non‐Hodgkin's malignant lymphoma, and 1 stomach cancer. The majority of second malignant tumors were amenable to some form of therapy, ie, surgery, radiation or chemotherapy. However, all of the acute myelogenous leukemias were totally refractory to any therapeutic modalities and rapidly expired. The majority of second cancers developed in patients receiving adjuvant chemotherapy. This is a patient population with a much longer expected survival time, particularly when compared to patients receiving chemotherapy for advanced disease. Twenty‐five of the 34 second cancers developed in patients who received adjuvant chemotherapy for breast (14) or colorectal (11) cancers. The etiology of the second malignancies is very difficult to determine. However, alkylating agents appeared to be the possible etiologic agent involved in the development of acute myelogenous leukemia.

AB - During the past 15 years, the records of 2,020 patients who received chemotherapy on the surgical oncology, chemotherapy service at the Pennsylvania Hospital were reviewed. Thirty‐five patients had pathologically confirmed second independent malignant tumors (not recurrences). The second cancers that developed were varied. The patients who developed these second malignancies ranged in age from 35 to 77 years (24 females, 11 males). The time interval involved was two to 102 months. Nine patients in this group of second malignancies received prior radiation therapy. The following is a list of the second cancers. There were 8 colons, 5 ovaries, 5 lungs, 6 acute myelogenous leukemias, 1 esophagus, 2 bladders, 2 epidermoid carcinomas of the skin, 2 melanomas, 1 chronic lymphatic leukemia, 1 breast cancer, 1 non‐Hodgkin's malignant lymphoma, and 1 stomach cancer. The majority of second malignant tumors were amenable to some form of therapy, ie, surgery, radiation or chemotherapy. However, all of the acute myelogenous leukemias were totally refractory to any therapeutic modalities and rapidly expired. The majority of second cancers developed in patients receiving adjuvant chemotherapy. This is a patient population with a much longer expected survival time, particularly when compared to patients receiving chemotherapy for advanced disease. Twenty‐five of the 34 second cancers developed in patients who received adjuvant chemotherapy for breast (14) or colorectal (11) cancers. The etiology of the second malignancies is very difficult to determine. However, alkylating agents appeared to be the possible etiologic agent involved in the development of acute myelogenous leukemia.

KW - 35 second malignancies

KW - chemotherapy

KW - patients

UR - http://www.scopus.com/inward/record.url?scp=0020565577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020565577&partnerID=8YFLogxK

U2 - 10.1002/jso.2930230315

DO - 10.1002/jso.2930230315

M3 - Article

C2 - 6575222

AN - SCOPUS:0020565577

VL - 23

SP - 195

EP - 197

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -